Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) saw strong trading volume on Friday after an insider bought additional shares in the company. 175,394 shares traded hands during mid-day trading, an increase of 10% from the previous session’s volume of 158,770 shares.The stock last traded at $4.63 and had previously closed at $4.52.
Specifically, major shareholder International S. Pharmstandard purchased 31,704 shares of the stock in a transaction that occurred on Friday, October 7th. The stock was bought at an average cost of $4.73 per share, for a total transaction of $149,959.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder International S. Pharmstandard purchased 67,371 shares of the stock in a transaction that occurred on Wednesday, August 24th. The stock was bought at an average price of $4.52 per share, with a total value of $304,516.92. The disclosure for this purchase can be found here. 61.64% of the stock is owned by corporate insiders.
A number of analysts recently issued reports on the company. Zacks Investment Research downgraded Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Monday, June 20th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Argos Therapeutics in a research report on Friday, June 17th. Finally, FBR & Co decreased their target price on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $11.50.
The stock’s market cap is $189.91 million. The company’s 50-day moving average is $4.89 and its 200 day moving average is $5.89.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Equities research analysts forecast that Argos Therapeutics Inc. will post ($1.56) EPS for the current year.
Several hedge funds have recently modified their holdings of the company. Schwab Charles Investment Management Inc. purchased a new stake in shares of Argos Therapeutics during the second quarter valued at approximately $137,000. Bridgeway Capital Management Inc. boosted its stake in shares of Argos Therapeutics by 66.9% in the second quarter. Bridgeway Capital Management Inc. now owns 135,924 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 54,500 shares during the last quarter. KCG Holdings Inc. purchased a new stake in shares of Argos Therapeutics during the second quarter valued at approximately $163,000. State Street Corp bought a new stake in shares of Argos Therapeutics during the second quarter valued at about $741,000. Finally, BlackRock Institutional Trust Company N.A. bought a new stake in shares of Argos Therapeutics during the second quarter valued at about $363,000. Hedge funds and other institutional investors own 11.05% of the company’s stock.